News & Media

Recent updates from Arcutis.

April 29, 2024

Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

April 10, 2024

Arcutis Appoints David Topper as Chief Financial Officer

April 5, 2024

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 28, 2024

Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference

March 11, 2024

Arcutis Promotes Todd Tucker to Chief Human Resources Officer

March 10, 2024

Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting

March 9, 2024

New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction

March 5, 2024

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 4, 2024

Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

March 4, 2024

Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting

February 29, 2024

Arcutis to Present at the TD Cowen 44th Annual Health Care Conference

February 28, 2024

Arcutis Announces Pricing of $150 Million Public Offering

Media Resources

Corporate Fact Sheet

Uncovering Psoriasis

Journal of the American Medical Association Roflumilast Cream 0.3% Result

Media Contact

Amanda Sheldon

805.418.5006
media@arcutis.com

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download